Johnson & Johnson is investing more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, specifically in Lower Gwynedd Township.
The facility, operated by subsidiary Janssen Biotech, will produce medicines for cancer, immune-mediated, and neurological diseases.
It will create over 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during development.
The announcement was made on February 18, 2026, and is part of J&J's $55 billion U.S. investment plan through early 2029.
Pennsylvania is supporting the project with a $41.5 million state investment, helping retain 5,885 full-time jobs statewide.
J&J's annual economic impact in Pennsylvania is approximately $10 billion, with ten facilities across the state.